Benedict R H B, Fishman I, McClellan M M, Bakshi R, Weinstock-Guttman B
Department of Neurology, State University of New York (SUNY), Buffalo School of Medicine and Biomedical Sciences, Buffalo General Hospital, Buffalo, New York 14203, USA.
Mult Scler. 2003 Aug;9(4):393-6. doi: 10.1191/1352458503ms902oa.
The Beck Depression Inventory-Fast Screen (BDI-FS) is a brief self-report inventory designed to evaluate depression in patients with medical illness. As depressive disorder is especially prominent in multiple sclerosis (MS), a cost-effective procedure for identifying depressive disorder in MS is sorely needed. The BDI-FS may be useful in this regard although, to date, its validity in MS patients has not been assessed.
Fifty-four consecutive MS patients were studied. All underwent psychological assessment, which included the BDI-FS and other self-report measures of depression. Forty-eight caregiver/informants were interviewed using the Neuorpsychiatric Inventory (NPI). Retrospective chart reviews were conducted by a single trained research assistant, blind to the results of psychological testing and interviews, to determine if antidepressant medications had been prescribed.
The BDI-FS was significantly correlated with other self-report measures of depression (P < 0.001) and with informant reported dysphoria (P < 0.01), In addition, BDI-FS scores discriminated MS patients undergoing treatment for depressive disorder from untreated MS patients (P = 0.01).
These data support the concurrent and discriminative validity of the BDI-FS in MS. As the test is brief and not confounded with neurological symptoms, it is recommended for depression screening in this population.
贝克抑郁量表快速筛查版（BDI - FS）是一种简短的自我报告量表，旨在评估患有内科疾病患者的抑郁情况。由于抑郁症在多发性硬化症（MS）患者中尤为突出，因此迫切需要一种经济有效的方法来识别MS患者中的抑郁症。尽管到目前为止，BDI - FS在MS患者中的有效性尚未得到评估，但它在这方面可能会有所帮助。
对54例连续的MS患者进行了研究。所有患者均接受了心理评估，包括BDI - FS和其他抑郁症自我报告量表。使用神经精神科问卷（NPI）对48名照料者/提供信息者进行了访谈。由一名经过培训的研究助理进行回顾性病历审查，该助理对心理测试和访谈结果不知情，以确定是否曾开具抗抑郁药物。
BDI - FS与其他抑郁症自我报告量表显著相关（P < 0.001），与提供信息者报告的烦躁不安显著相关（P < 0.01）。此外，BDI - FS评分能够区分正在接受抑郁症治疗的MS患者和未接受治疗的MS患者（P = 0.01）。
这些数据支持BDI - FS在MS中的同时效度和区分效度。由于该测试简短且不受神经症状干扰，建议用于该人群的抑郁症筛查。
